• Reference Citation Analysis
  • v
  • v
  • Find an Article
Find an Article PDF (4615863)   Today's Articles (1140)   Subscriber (49393)
Download
Number Citation Analysis
101
Liu X, Gao J, Liu S, Cheng Y, Hao L, Liu S, Zhu W. The uniqueness and superiority of energy utilization in yaks compared with cattle in the highlands: A review. ANIMAL NUTRITION (ZHONGGUO XU MU SHOU YI XUE HUI) 2022;12:138-144. [PMID: 36683881 PMCID: PMC9841238 DOI: 10.1016/j.aninu.2022.09.011] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 10/08/2021] [Revised: 09/22/2022] [Accepted: 09/26/2022] [Indexed: 11/05/2022]
102
Geng X, Lei J, Bau T, Guo D, Chang M, Feng C, Xu L, Cheng Y, Zuo N, Meng J. Purification, Characterization, and Immobilization of a Novel Protease-Resistant α-Galactosidase from Oudemansiella radicata and Its Application in Degradation of Raffinose Family Oligosaccharides from Soymilk. Foods 2022;11:foods11193091. [PMID: 36230167 PMCID: PMC9563442 DOI: 10.3390/foods11193091] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/29/2022] [Revised: 09/21/2022] [Accepted: 10/01/2022] [Indexed: 11/16/2022]  Open
103
Bukis K, Cheng Y, Armstrong M, Conte J, Coote K, Allaire N, Sivachenko A, Mense M, Cotton C, Valley H. 634 Generation of a cystic fibrosis transmembrane conductance regulator R1162X “TAG” model and comparison of readthrough to the naturally occurring R1162X “TGA”. J Cyst Fibros 2022. [PMCID: PMC9527874 DOI: 10.1016/s1569-1993(22)01324-8] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Download PDF] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]
104
Allaire N, Yoon J, Armstrong M, Valley H, Macadino C, Sivachenko A, Conte J, Tabak B, Bihler H, Cheng Y, Coote K, Cotton C, Mense M. 663 Modulation of cystic fibrosis transmembrane conductance regulator intron 22 alternative polyadenylation use may have therapeutic potential for the treatment of certain 3′ cystic fibrosis transmembrane conductance regulator premature termination codon variants. J Cyst Fibros 2022. [DOI: 10.1016/s1569-1993(22)01353-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/06/2022]
105
Liu X, Li J, Hao L, Degen A, Wang D, Ma Y, Niu J, Cheng Y, Liu S. Effect of the ratio of dietary metabolizable energy to nitrogen content on production performance, serum metabolites, rumen fermentation parameters, and bacterial diversity in yaks. Front Microbiol 2022;13:1013980. [PMID: 36304954 PMCID: PMC9593094 DOI: 10.3389/fmicb.2022.1013980] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/08/2022] [Accepted: 09/02/2022] [Indexed: 11/13/2022]  Open
106
Qiao Z, Zhao Y, Wang M, Cao J, Chang M, Yun S, Cheng Y, Cheng F, Feng C. Effects of Sparassis latifolia neutral polysaccharide on immune activity via TLR4-mediated MyD88-dependent and independent signaling pathways in RAW264.7 macrophages. Front Nutr 2022;9:994971. [PMID: 36185691 PMCID: PMC9515474 DOI: 10.3389/fnut.2022.994971] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/15/2022] [Accepted: 08/15/2022] [Indexed: 11/13/2022]  Open
107
Xiao M, Wu S, Cheng Y, Ma J, Luo X, Chang L, Zhang C, Chen J, Zou L, You Y, Zhang J. Colon-specific delivery of isoliquiritigenin by oral edible zein/caseate nanocomplex for ulcerative colitis treatment. Front Chem 2022;10:981055. [PMID: 36157029 PMCID: PMC9501975 DOI: 10.3389/fchem.2022.981055] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/29/2022] [Accepted: 08/23/2022] [Indexed: 01/17/2023]  Open
108
Cheng Y, Xiao M, Chen J, Wang D, Hu Y, Zhang C, Wang T, Fu C, Wu Y, Zhang J. Quality assessment and Q-markers discovery of Tongsaimai tablet by integrating serum pharmacochemistry and network pharmacology for anti-atherosclerosis benefit. Chin Med 2022;17:103. [PMID: 36056398 PMCID: PMC9438231 DOI: 10.1186/s13020-022-00658-9] [Citation(s) in RCA: 10] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/12/2022] [Accepted: 08/22/2022] [Indexed: 11/10/2022]  Open
109
Rodriguez-Abreu D, Wu YL, Boyer M, Garassino M, Mok T, Cheng Y, Hui R, Kowalski D, Robinson A, Brahmer J, Leal T, Lopes G, Cho B, Nogami N, Novello S, Peled N, de Castro G, Leiby M, Chirovsky D, Lin J, Pietanza M, Reck M. OA15.06 Pooled Analysis of Outcomes with Second-Course Pembrolizumab Across 5 Phase 3 Studies of Non-Small-Cell Lung Cancer. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.075] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
110
Cheng Y, Wu L, Huang D, Wang Q, Fan Y, Liu Z, Fan H, Yao W, Liu B, Yu G, Pan Y, Xu F, He Z, Dong X, Ma R, Min X, Ge X, Chen H, Liu Q, Hu Y, Liu Y, Song W, Yang C, Sun S. EP08.02-078 Myeloprotection with Trilaciclib in Chinese Patients with Extensive-Stage Small Cell Lung Cancer Receiving Standard Chemotherapy (TRACES). J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.760] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
111
Wang J, Cheng Y, Wu Y, Cao F, Liu Q, Gao G. 1262TiP Efficacy and safety of consolidative camrelizumab following definitive concurrent chemoradiotherapy in patients with locally advanced esophageal squamous cell cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1880] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]  Open
112
Smit E, Felip E, Uprety D, Nakagawa K, Paz-Ares L, Pacheco J, Li B, Planchard D, Baik C, Goto Y, Murakami H, Saltos A, Saxena K, Shiga R, Cheng Y, Yan Q, Feng W, Jänne P. 975P Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1103] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]  Open
113
John T, Ciuleanu TE, Cobo Dols M, Schenker M, Zurawski B, Menezes J, Richardet E, Bennouna J, Cheng Y, Felip E, Juan Vidal O, Alexandru A, Paz-Ares L, Lu S, Reck M, Hu N, Zhang X, Grootendorst D, Eccles L, Carbone D. 1049P Clinical outcomes in patients (pts) with tumor PD-L1 < 1% with first-line (1L) nivolumab (NIVO) + ipilimumab (IPI) + 2 cycles of chemotherapy (chemo) vs chemo alone for metastatic NSCLC (mNSCLC): Results from CheckMate 9LA. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1175] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]  Open
114
Li B, Smit E, Goto Y, Nakagawa K, Goto K, Mazieres J, Uprety D, Bazhenova L, Saltos A, Felip E, Pacheco J, Pérol M, Paz-Ares L, Saxena K, Shiga R, Cheng Y, Yan Q, Planchard D, Jänne P. 976P Phase II trial of trastuzumab deruxtecan (T-DXd) in patients (Pts) with HER2-mutated (HER2m) metastatic non-small cell lung cancer (NSCLC): Registrational data from DESTINY-Lung01. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1104] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/26/2022]  Open
115
Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, Ma Z, Wang Z, Cheng Y, Wang J, Hu S, Liu Z, Poddubskaya E, Disel U, Akopov A, Dvorkin M, Wang Y, Li S, Yu C, Rivalland G. EP08.01-014 Tislelizumab versus Docetaxel in Previously Treated Advanced Non-Small Cell Lung Cancer: Final Analysis of RATIONALE-303. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.586] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/29/2022]
116
Ding K, Liu Y, Song Y, Xu D, Li J, Wang J, Chen X, Lin R, Jiang Y, Zhang Y, Zhang W, Cheng Y, Wu X, Yuan Y. 441TiP A multicenter, randomized, open-label, phase III study of anlotinib plus CAPEOX versus bevacizumab plus CAPEOX as first-line therapy in patients with RAS/BRAF wild-type metastatic colorectal cancer. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1862] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/15/2022]  Open
117
Wang M, Yang JH, Mitchell P, Fang J, Nian W, Chiu C, Zhou J, Zhao Y, Su WC, Camidge D, Yang TY, Zhu V, Millward M, Fan Y, Cheng Y, Jiang L, Zheng L, Jänne P. 987P Sunvozertinib for NSCLC patients with EGFR exon 20 insertion mutations: Preliminary analysis of WU-KONG6, the first pivotal study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1114] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]  Open
118
Lu S, Zhang Y, Zhang G, Zhou J, Cang S, Cheng Y, Wu G, Cao P, Lv D, Jian H, Chen C, Jin X, Tian P, Wang K, Jiang G, Chen G, Chen Q, Zhao H, Ding C, Guo R, Sun G, Wang B, Jiang L, Liu Z, Fang J, Yang J, Zhuang W, Liu Y, Zhang J, Pan Y, Chen J, Yu Q, Zhao M, Cui J, Li D, Yi T, Yu Z, Yang Y, Zhang Y, Zhi X, Huang Y, Wu R, Chen L, Zang A, Cao L, Li Q, Li X, Song Y, Wang D, Zhang S. EP08.02-139 A Phase 2 Study of Befotertinib in Patients with EGFR T790M Mutated NSCLC after Prior EGFR TKIs. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.822] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
119
Zhou C, Huang D, Fan Y, Yu X, Liu Y, Shu Y, Ma Z, Wang Z, Cheng Y, Wang J, Hu S, Poddubskaya E, Disel U, Akopov A, Dvorkin M, Wang Y, Ghassemifar S, Li S, Rivalland G. 1031P Tislelizumab (TIS) versus docetaxel (TAX) as second- or third-line therapy in previously treated patients (pts) with locally advanced non-small cell lung cancer (NSCLC): Asian versus non-Asian subgroup analysis of the RATIONALE-303 study. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1157] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]  Open
120
Novello S, Kowalski D, Luft A, Gumus M, Vicente Baz D, Mazieres J, Rodriguez Cid J, Tafreshi A, Cheng Y, Lee K, Golf A, Sugawara S, Robinson A, Halmos B, Jensen E, Schwarzenberger P, Pietanza M, Paz-Ares L. 974MO 5-year update from KEYNOTE-407: Pembrolizumab plus chemotherapy in squamous non-small cell lung cancer (NSCLC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.1102] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]  Open
121
Li J, Pu X, Zhang B, Zhang J, Mok T, Nakagawa K, Rosell R, Cheng Y, Zhou X, Migliorino M, Niho S, Lee K, Corral J, Pluzanski A, Li J, Linke R, Pan F, Tang Y, Tan W, Wu L. EP08.02-159 Post Hoc Analyses of Dacomitinib-Associated Skin Disorders and Efficacy in the ARCHER 1050 Study. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.842] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
122
Kumar R, Kim S, Zhong D, Lu S, Cheng Y, Chen M, Cho E, Clay T, Kang JH, Lee GW, Sun M, Shim BY, Spigel D, Yang TY, Wang Q, Chang GC, Yu G, Wang R, Luo X, Zheng H, Gao R, Kim H. EP08.01-073 AdvanTIG-105: Phase 1b Dose-Expansion Study of Ociperlimab plus Tislelizumab in Patients with Metastatic NSCLC. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.645] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
123
Kasper S, Segal N, Rivera F, Tournigand C, Cheng Y, Deshpande P, Amirouchene Angelozzi N, Bento Pereira da Silva A, St-Pierre A, Kopetz S. 132TiP Biomarker assessments in daNIS-3: A phase II study of NIS793 and other new investigational drug combinations with standard-of-care (SoC) therapy vs SoC alone for the second-line treatment of patients (pts) with metastatic colorectal adenocarcinoma (mCRC). Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.07.164] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/24/2022]  Open
124
Xu B, Zhang Q, Zhang P, Tong Z, Sun T, Li W, Ouyang Q, Hu X, Cheng Y, Yan M, Teng Y, Pan Y, Yan X, Wang Y, Xie W, Zeng X, Jiang S, Bayaxi N, Zhu X. LBA16 Dalpiciclib plus letrozole or anastrozole as first-line treatment for HR+/HER2- advanced breast cancer (DAWNA-2): A phase III trial. Ann Oncol 2022. [DOI: 10.1016/j.annonc.2022.08.010] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]  Open
125
Wu YL, Zhou Q, Chen M, Pan Y, Jian O, Hu D, Lin Q, Wu G, Cui J, Chang J, Cheng Y, Huang C, Liu A, Yang N, Gong Y, Zhu C, Ma Z, Fang J, Chen G, Zhao J, Shi A, Lin Y, Li G, Liu Y, Wang D, Wu R, Xu X, Shi J, Liu Z, Wang J, Yang J. OA02.05 Sugemalimab vs Placebo after cCRT or sCRT in pts with Unresectable Stage III NSCLC: Final PFS Analysis of a Phase 3 Study. J Thorac Oncol 2022. [DOI: 10.1016/j.jtho.2022.07.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
PrevPage 5 of 57 124565657Next
© 2004-2024 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA